Rafinlar 50mg Capsule contains dabrafenib 50mg, a prescription targeted anticancer medicine and BRAF kinase inhibitor used for selected cancers with eligible BRAF V600 mutations. Dabrafenib is used in approved treatment regimens for BRAF V600 mutation-positive melanoma and, in combination with trametinib, certain BRAF V600 mutation-positive cancers including non-small cell lung cancer and other approved indications depending on the country.
Rafinlar is the branded formulation of dabrafenib marketed by Novartis. The 50mg capsule provides a lower capsule strength that may be used as part of individualized oncology dosing or dose adjustments according to the prescribing oncologist’s instructions.
Because dabrafenib is a biomarker-directed cancer medicine, appropriate BRAF mutation testing is required before treatment. Rafinlar should be used only under specialist oncology supervision.
Rafinlar 50mg is an oral targeted cancer medicine containing dabrafenib.
Dabrafenib is designed to inhibit abnormal signaling produced by mutated BRAF proteins. Certain cancers acquire activating BRAF mutations that can continuously stimulate pathways responsible for cell growth and proliferation.
By selectively inhibiting mutant BRAF kinase activity, dabrafenib can interfere with this abnormal signaling and help slow cancer-cell growth in appropriately selected patients.
Rafinlar/dabrafenib is used for cancers carrying specific BRAF mutations where the treatment is approved.
Depending on the applicable regulatory indication, dabrafenib-based treatment may be used for:
The exact indications and treatment combinations vary between regulatory jurisdictions. Treatment should follow the current prescribing information applicable to the patient’s country.
Dabrafenib inhibits BRAF kinase, an important component of the RAS/RAF/MEK/ERK (MAPK) signaling pathway.
In cancers containing activating BRAF V600 mutations, this pathway can become excessively active, promoting uncontrolled cellular proliferation.
Dabrafenib blocks mutant BRAF signaling, reducing downstream pathway activity and helping inhibit the growth of cancer cells containing susceptible BRAF mutations.
Rafinlar is a molecularly targeted therapy, meaning the patient’s cancer must have an appropriate molecular characteristic for treatment.
Before starting dabrafenib, the relevant BRAF V600 mutation should be confirmed using an appropriate validated diagnostic test.
This creates the primary search relationship:
Rafinlar 50mg → Dabrafenib 50mg → BRAF Inhibitor → BRAF V600 Mutation → Targeted Cancer Therapy
For several approved indications, dabrafenib is administered in combination with trametinib, a MEK inhibitor.
The combination inhibits the MAPK pathway at two different points, providing more comprehensive suppression of abnormal BRAF/MEK signaling in appropriately selected BRAF V600 mutation-positive cancers.
The dose and combination regimen must be determined by the treating oncologist.
Rafinlar dosage is individualized according to the cancer type, BRAF mutation status, treatment regimen, patient characteristics, adverse reactions and clinical response.
The 50mg capsule may be used as part of a prescribed dosing regimen or for dose modification when clinically appropriate.
Patients should take Rafinlar exactly as prescribed. Capsules should be swallowed whole and should not be opened, crushed or chewed unless specifically instructed by a healthcare professional.
Do not increase, reduce or discontinue the medicine without consulting the treating oncologist.
Dabrafenib can cause adverse effects, and the safety profile may differ when it is administered alone or together with trametinib.
Possible adverse effects include:
Serious adverse reactions can also occur, including severe fever-related reactions, bleeding, eye disorders, cardiac effects, liver abnormalities and new skin malignancies.
Patients should promptly contact their oncology team if they develop severe or persistent symptoms.
Store Rafinlar according to the conditions stated on the official product packaging and prescribing information.
Keep the capsules in their original container and away from children. Do not use the product after its expiry date.
The active pharmaceutical ingredient in Rafinlar is dabrafenib.
Where an appropriately authorized generic or equivalent product is available, commercially relevant searches may include:
Generic Rafinlar 50mg, Dabrafenib 50mg, Generic Dabrafenib 50mg, Dabrafenib 50mg Capsule, Rafinlar Alternative, Dabrafenib Alternative
The term Generic Rafinlar should only be used where the specific product has the appropriate regulatory status in the relevant market.
Rafinlar 50mg Capsule is a prescription oncology medicine and should be obtained through an appropriately licensed pharmacy or authorized pharmaceutical supplier.
Commercial searches include Rafinlar 50mg Capsule, Buy Rafinlar 50mg, Buy Dabrafenib 50mg, Rafinlar 50mg Price, Dabrafenib 50mg Price, Generic Rafinlar 50mg, Dabrafenib 50mg Supplier, Rafinlar Online and related transactional terms.
Availability, prescription requirements, importation and dispensing regulations differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Rafinlar contains dabrafenib and is used for selected cancers with an eligible BRAF V600 mutation, including certain patients with unresectable or metastatic melanoma. Dabrafenib with trametinib is also used for several other approved BRAF V600 mutation-positive cancers.
The generic name is dabrafenib. Rafinlar 50mg contains dabrafenib as its active pharmaceutical ingredient.
Yes. Dabrafenib is a selective BRAF kinase inhibitor targeting mutant BRAF signaling.
Yes. Dabrafenib is used for eligible patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to the applicable treatment indication.
Dabrafenib, in combination with trametinib, is approved for certain patients with BRAF V600 mutation-positive advanced non-small cell lung cancer.
Yes. Appropriate molecular testing is required to determine whether the tumor contains the relevant BRAF mutation for which dabrafenib is indicated.
Rafinlar is the brand name, while dabrafenib is the active pharmaceutical ingredient. An authorized generic dabrafenib product may have a different brand name and manufacturer.
The treatment regimen depends on the specific cancer and regulatory indication. Dabrafenib may be used alone for certain approved melanoma treatment situations, while combination with trametinib is used for several other indications.
Rafinlar is a prescription anticancer medicine. It should be purchased only from an appropriately licensed pharmacy or authorized supplier and used under specialist oncology supervision.
Common adverse effects may include fever, fatigue, headache, nausea, vomiting, diarrhea, joint pain, decreased appetite and skin reactions. Your oncologist should be informed about persistent or severe symptoms.
Yes. Patients receiving dabrafenib require appropriate oncology monitoring for treatment response and potential adverse effects. Depending on the treatment regimen, monitoring may include clinical assessment, blood tests, skin examinations, eye evaluation, liver function and cardiovascular assessment.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Rafinlar (dabrafenib) is a prescription targeted anticancer medicine that requires specialist oncology supervision. Treatment depends on appropriate molecular testing and the specific approved indication. Dabrafenib may cause serious and potentially life-threatening adverse reactions. Always follow the official prescribing information for the specific product and consult a qualified oncologist before starting, stopping or changing treatment.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Paramjit –
Ordered for my parents in Panjab from USA. They promised to deliver medicine, and did exactly the same. Thanks
NITESH KHARE –
Excellent service and trust worthy 👍
Jilani Uddin Shaikh –
Delivery👍